{"id":"NCT05795153","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.","officialTitle":"A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-04-05","primaryCompletion":"2024-04-25","completion":"2024-04-25","firstPosted":"2023-04-03","resultsPosted":"2025-04-30","lastUpdate":"2025-04-30"},"enrollment":144,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"DRUG","name":"LOU064","otherNames":["remibrutinib"]}],"arms":[{"label":"LOU064 (remibrutinib)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess the effect of remibrutinib 25 mg twice a day (b.i.d.) open-label on Systolic Blood Pressure (SBP) measured as a change in 24-hour weighted average SBP from baseline to Week 4 assessed by Ambulator Blood Pressure Monitoring (ABPM); and to assess overall safety and efficacy over 12 weeks in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled with second generation H1 antihistamines (H1-AH) treatment. ABPM was chosen for the blood pressure assessment in this trial as recommended by the FDA for drugs intended for chronic use (Assessment of Pressor Effects of Drugs Guidance for Industry (FDA 2022)).","primaryOutcome":{"measure":"Estimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM)","timeFrame":"Baseline, Week 4","effectByArm":[{"arm":"LOU064 (Remibrutinib)","deltaMin":-1.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":44,"countries":["United States","Argentina","Canada","France","Germany","Singapore","Slovakia","South Korea","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":144},"commonTop":["Headache","Nasopharyngitis","Chronic spontaneous urticaria"]}}